The prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is very poor although sorafenib is recommended as the first-line treatment. Therefore, an effective treatment regime is needed for treating HCC with PVTT. This review summarized seven potential treatment regimes which including transarterial chemoembolization (TACE), TACE combined with sorafenib, TACE combined with radiotherapy (RT), hepatectomy, hepatic arterial infusion chemotherapy (HAIC), HAIC combined with sorafenib and HAIC combined with RT in the treatment of HCC with PVTT. In conclusion, hepatectomy or the combination of HAIC and sorafenib may be a more effective modality in the treatment of HCC patients with type I - II PVTT. HAIC combined with or without sorafenib/RT or the combination of RT and TACE is an alternative treatment choice for HCC patients with type III - IV PVTT. Further randomized controlled studies are warranted.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
Heimbach, J.K., Kulik, L.M., Finn, R.S., Sirlin, C.B., Abecassis, M.M., Roberts, L.R., et al. (2018) AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67, 358-380. https://doi.org/10.1002/hep.29086
European Association for the Study of the Liver. Electronic Address EEE, European Association for the Study of the L (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
Omata, M., Cheng, A.L., Kokudo, N., Kudo, M., Lee, J.M., Jia, J., et al. (2017) Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update. Hepatology International, 11, 317-370. https://doi.org/10.1007/s12072-017-9799-9
Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
Llovet, J.M., Bustamante, J., Castells, A., Vilana, R., Ayuso Mdel, C., Sala, M., et al. (1999) Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials. Hepatology, 29, 62-67. https://doi.org/10.1002/hep.510290145
Zhang, Z.Y., Dong, K.S., Zhang, E.L., Zhang, L.W., Chen, X.P. and Dong, HH. (2019) Resection Might Be a Meaningful Choice for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Systematic Review and Meta-Analysis. Medicine, 98, e18362. https://doi.org/10.1097/MD.0000000000018362
Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
Bruix, J., Cheng, A.L., Meinhardt, G., Nakajima, K., De Sanctis, Y. and Llovet, J. (2017) Prognostic Factors and Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma: Analysis of Two Phase III Studies. Journal of Hepatology, 67, 999-1008. https://doi.org/10.1016/j.jhep.2017.06.026
Luo, J., Guo, R.P., Lai, E.C., Zhang, Y.J., Lau, W.Y., Chen, M.S., et al. (2011) Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. Annals of Surgical Oncology, 18, 413-420. https://doi.org/10.1245/s10434-010-1321-8
Niu, Z.J., Ma, Y.L., Kang, P., Ou, S.Q., Meng, Z.B., Li, Z.K., et al. (2012) Transarterial Chemoembolization Compared with Conservative Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Using a New Classification. Medical Oncology, 29, 2992-2997. https://doi.org/10.1007/s12032-011-0145-0
Xiang, X., Lau, W.Y., Wu, Z.Y., Zhao, C., Ma, Y.L., Xiang, B.D., et al. (2019) Transarterial Chemoembolization versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombusa Multicenter Study. European Journal of Surgical Oncology, 45, 1460-1467. https://doi.org/10.1016/j.ejso.2019.03.042
Pinter, M., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Konigsberg, R., et al. (2012) Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology, 263, 590-599. https://doi.org/10.1148/radiol.12111550
Chung, J.W., Park, J.H., Han, J.K., Choi, B.I., Han, M.C., Lee, H.S., et al. (1996) Hepatic Tumors: Predisposing Factors for Complications of Transcatheter Oily Chemoembolization. Radiology, 198, 33-40. https://doi.org/10.1148/radiology.198.1.8539401
Choi, G.H., Shim, J.H., Kim, M.J., Ryu, M.H., Ryoo, B.Y., Kang, Y.K., et al. (2013) Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. Radiology, 269, 603-611. https://doi.org/10.1148/radiol.13130150
Yuan, J., Yin, X., Tang, B., Ma, H., Zhang, L., Li, L., et al. (2019) Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International, 2019, Article ID: 2141859. https://doi.org/10.1155/2019/2141859
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.Y., Takayama, T., et al. (2011) Phase III Study of Sorafenib after Transarterial Chemoembolisation in Japanese and Korean Patients with Unresectable Hepatocellular Carcinoma. European Journal of Cancer, 47, 2117-2127. https://doi.org/10.1016/j.ejca.2011.05.007
Li, X.L., Guo, W.X., Hong, X.D., Yang, L., Wang, K., Shi, J., et al. (2016) Efficacy of the Treatment of Transarterial Chemoembolization Combined with Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Analysis. Hepatology Research, 46, 1088-1098. https://doi.org/10.1111/hepr.12657
Lu, D.H., Fei, Z.L., Zhou, J.P., Hu Z.T. and Hao, W.S. (2015) A Comparison between Three-Dimensional Conformal Radiotherapy Combined with Interventional Treatment and Interventional Treatment Alone for Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis. Journal of Medical Imaging and Radiation Oncology, 59, 109-114. https://doi.org/10.1111/1754-9485.12207
Wang, K., Guo, W.X., Chen, M.S., Mao, Y.L., Sun, B.C., Shi, J., et al. (2016) Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine, 95, e3015. https://doi.org/10.1097/MD.0000000000003015
Kang, J., Nie, Q., Du, R., Zhang, L., Zhang, J., Li, Q., et al. (2014) Stereotactic Body Radiotherapy Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Molecular and Clinical Oncology, 2, 43-50. https://doi.org/10.3892/mco.2013.196
Liu, P.H., Lee, Y.H., Hsu, C.Y., Hsia, C.Y., Huang, Y.H., Chiou, Y.Y., et al. (2014) Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma beyond Milan Criteria Independent of Performance Status. The Journal of Gastrointestinal Surgery, 18, 1623-1631. https://doi.org/10.1007/s11605-014-2546-9
Zhao, Y.N., Zhang, Y.Q., Ye, J.Z., Liu, X., Yang, H.Z., Cong, F.Y., et al. (2016) Hepatic Resection versus Transarterial Chemoembolization for Patients with Barcelona Clinic Liver Cancer Intermediate Stage Child-Pugh A Hepatocellular Carcinoma. Experimental and Therapeutic Medicine, 12, 3813-3819. https://doi.org/10.3892/etm.2016.3810
Peng, Z.W., Guo, R.P., Zhang, Y.J., Lin, X.J., Chen, M.S. and Lau, W.Y. (2012) Hepatic Resection versus Transcatheter Arterial Chemoembolization for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cancer, 118, 4725-4736. https://doi.org/10.1002/cncr.26561
Zheng, N., Wei, X., Zhang, D., Chai, W., Che, M., Wang, J., et al. (2016) Hepatic Resection or Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Medicine, 95, e3959. https://doi.org/10.1097/MD.0000000000003959
Lee, J.M., Jang, B.K., Lee, Y.J., Choi, W.Y., Choi, S.M., Chung, W.J., et al. (2016) Survival Outcomes of Hepatic Resection Compared with Transarterial Chemoembolization or Sorafenib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Clinical and Molecular Hepatology, 22, 160-167. https://doi.org/10.3350/cmh.2016.22.1.160
Choi, J.H., Chung, W.J., Bae, S.H., Song, D.S., Song, M.J., Kim, Y.S., et al. (2018) Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. https://doi.org/10.1007/s00280-018-3638-0
Song, D.S., Song, M.J., Bae, S.H., Chung, W.J., Jang, J.Y., Kim, Y.S., et al. (2015) A Comparative Study between Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. The Journal of Gastroenterology, 50, 445-454. https://doi.org/10.1007/s00535-014-0978-3
Nakano, M., Niizeki, T., Nagamatsu, H., Tanaka, M., Kuromatsu, R., Satani, M., et al. (2017) Clinical Effects and Safety of Intra-Arterial Infusion Therapy of Cisplatin Suspension in Lipiodol Combined with 5-Fluorouracil versus Sorafenib, for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion without Extra-Hepatic Spread: A Prospective Cohort Study. Molecular and Clinical Oncology, 7, 1013-1020. https://doi.org/10.3892/mco.2017.1442
Nagai, H., Mukozu, T., Ogino, Y.U., Matsui, D., Matsui, T., Wakui, N., et al. (2015) Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Anticancer Research, 35, 2269-2277.
He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., et al. (2019) Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
Onishi, H., Nouso, K., Nakamura, S., Katsui, K., Wada, N., Morimoto, Y., et al. (2015) Efficacy of Hepatic Arterial Infusion Chemotherapy in Combination with Irradiation for Advanced Hepatocellular Carcinoma with Portal Vein Invasion. Hepatology International, 9, 105-112. https://doi.org/10.1007/s12072-014-9592-y
Kodama, K., Kawaoka, T., Aikata, H., Uchikawa, S., Nishida, Y., Inagaki, Y., et al. (2018) Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Oncology, 94, 215-222. https://doi.org/10.1159/000486483